HER2 has been extensively studied as a therapeutic target, and an FDA-approved monoclonal antibody, Trastuzumab, has been shown to be effective in treating patients with HER2-overexpressing breast cancer [23]. The gene discussed is ERBB2; the disease is breast cancer.